CHRONIC LYMPHOCYTIC LEUKEMIAFROM GENETICS TO TAYLORED THERAPY

来源 :中华医学会第十三次全国白血病·淋巴瘤学术会议 | 被引量 : 0次 | 上传用户:houlitao2009
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Division of Hematology, Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy The clinical course of chronic lymphocytic leukemia (CLL) is extremely heterogeneous.Understanding CLL genetics may help clarify the molecular bases of the clinical heterogeneity of this leukemia.In 2000, this notion was unequivocally documented by D(o)hner et al.who established interphase FISH analysis as a standard technique to evaluate cytogenetic lesions in CLL.Cytogenetic lesions, however, do not entirely explain the genetic basis of the clinical heterogeneity of CLL.
其他文献
会议
AML
会议
会议
会议
Tamibarotene, (4[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl) carbamoyl] benzoic acid),may be the most attractive synthetic retinoid.It is about 10 t
会议
OutlneEpidemiology Founding Diagnostic techniques AML ALL Epidemiology Annual Incidence of Leukemia 2.76/105 Male: 2.98/105, Female: 2.58/105 AML: 1.62/105 ALL:
会议
Defining minimal residual disease in AML: which platforms are ready for "prime time"Why detect MRD in AML? Application of assays to detect submicroscopic levels
会议
  Many studies have clearly demonstrated that in CML cytogenetic and molecular responses are strictly correlated to the final outcome of the patients and the
会议